Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 26 September 2019, 13:08 HKT/SGT
Share:
    

Source: Eisai
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients

TOKYO, Sept 26, 2019 - (JCN Newswire) - Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019. The Coroban predicts inpatients' tumbling and falling risks in advance and displays alerts.

Through the launch of antiosteoporotic agent and insomnia treatment, a pharmaceutical company Eisai has recognized that the preventive measures for tumbling and falling at medical institutions are important. On the other hand, FRONTEO Healthcare, Inc., a wholly owned subsidiary of FRONTEO, is a data analysis corporation focused on healthcare. It has originally developed an artificial intelligence (AI) system called Concept Encoder based on natural language processing technique.

Eisai and FRONTEO have started the joint development for the Coroban since January 2018. The Coroban was introduced to several medical institutions in Japan on a trial basis by leveraging Eisai's network with medical institutions, and advancing the improvements of Coroban based on needs in the clinical settings has led to the launch of the Coroban this time.

According to a survey by the Ministry of Health, Labour and Welfare, the number of inpatients aged 65 and over tends to increase to about 960,000 in 2017, therefore, the importance of cares for tumbling and falling in medical institutions is increasing. The Coroban learns the nursing records of past inpatients at each medical institution, scores the tumbling and falling risks of individual inpatient from the daily nursing records based on these past records, and displays the information of inpatients with high risks. It is expected to reduce the burden of medical professionals and to make the risk assessment uniform and objective by reflecting the information in individual care and nursing plans for each patient's tumbling and falling with the Coroban.

Through the launch of the Coroban which supports to establish systems at nursing ward to reduce the tumbling and falling risks of inpatients, Eisai and Fronteo aim to contribute to the realization of well-being of patients and their families.

About the tumbling and falling prediction system Coroban

Product name: Tumbling and Falling Prediction System Coroban
* The Coroban is not a medical device.

About Concept Encoder AI system

Concept Encoder is the AI system developed by FRONTEO Healthcare. Inc. specifically for the healthcare industry. The system was developed with the aim of effective, evidence-based analysis and utilization of healthcare-related big data, including large bodies of free-entry text data. The program incorporates significance tests and other crucial statistical methods for evidence-based medicine (EBM), the gold standard of practice among healthcare professionals, and applies this to natural language analysis. For more information, visit https://www.fronteo- healthcare.com/conceptencoder.

About FRONTEO, Inc. and FRONTEO Healthcare, Inc.

FRONTEO, Inc. supports the analysis of big data based on behavior informatics by utilizing its originally developed AI technology, "KIBIT". FRONTEO was found in 2003, and has ever since been developing our business primarily in the field of LegalTech including "eDiscovery" (preserve, process review, and analyze electronically stored data that could be evidence doe litigation process) and "digital forensics", as well as initiatives "Securely Identify Risks and Opportunities Buried in Records" in the field of business intelligence. FRONTEO Healthcare, Inc. was found in 2015. Through its data analysis capability, FRONTEO Healthcare, Inc. hopes to support people around the world in receiving the best healthcare services and pave the way to a healthier, more secure future.

For more information about FRONTEO, Inc. and FRONTEO Healthcare, Inc., please visit http://www.fronteo.com/ http://www.fronteo-healthcare.com/


Contact:
Media Inquiries:
Eisai Co., Ltd.
Public Relations Department 
TEL: +81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: